Of note, patients with melanoma progression against B-Raf inhibitor monotherapy may benefit from a combination of B-Raf/MEK inhibitors [33], while anti-MEK monotherapy against the background of anti-B-Raf TT resistance is non-efficacious. This evidence concerns the gene MAP2K7 and melanoma.